Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
Last updated on April 2022Recruitment
- Recruitment Status
- Unknown status
Inclusion Criteria
- Life expectancy ≥2 months;
- histologically confirmed with malignant tumor;
- Adequate bone marrow, cardiac, liver, and renal function;
- ...
- Life expectancy ≥2 months;
- histologically confirmed with malignant tumor;
- Adequate bone marrow, cardiac, liver, and renal function;
- Informed consent signed
- At least one measurable lesion according to the RECIST criteria;
- an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- Age: 18-80 years;
- Not received other anti-tumor treatment
Exclusion Criteria
- previous history of other malignancies;
- Uncontrolled central nervous system metastases;
- Serious or uncontrolled concurrent medical illness.
- previous history of other malignancies;
- Uncontrolled central nervous system metastases;
- Serious or uncontrolled concurrent medical illness.
Summary
- Conditions
- Malignant Tumor
- Type
- Interventional
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) . Venous blood (4 ml) is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are sorted by Fl...
The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) . Venous blood (4 ml) is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are sorted by Fluorescence Activated Cell Sorting(FACS) and stored at -80°C until processing. The T-Cell Receptor/B-Cell Receptor gene expression is detected by micro-array。 Estimate Immunotherapy response, time to disease progression, survival rates and clinical benefit response on patients. Response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups: sensitive and non-sensitive to immunotherapy. Compare the gene expression profile between different immunotherapy response groups to explore the mechanism that predict the DC-CIK immunotherapy response.
Inclusion Criteria
- Life expectancy ≥2 months;
- histologically confirmed with malignant tumor;
- Adequate bone marrow, cardiac, liver, and renal function;
- ...
- Life expectancy ≥2 months;
- histologically confirmed with malignant tumor;
- Adequate bone marrow, cardiac, liver, and renal function;
- Informed consent signed
- At least one measurable lesion according to the RECIST criteria;
- an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- Age: 18-80 years;
- Not received other anti-tumor treatment
Exclusion Criteria
- previous history of other malignancies;
- Uncontrolled central nervous system metastases;
- Serious or uncontrolled concurrent medical illness.
- previous history of other malignancies;
- Uncontrolled central nervous system metastases;
- Serious or uncontrolled concurrent medical illness.
Tracking Information
- NCT #
- NCT01906632
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon